Latest News, Press Releases & Events

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017

Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017 Study results indicate SPX-101 was well-tolerated with no dose limiting safety concerns Company has initiated plans for a Phase 2 study to investigate clinical benefit of SPX-101 in treating cystic fibrosis-related lung disease, […]

Continue Reading

Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Safety, Stability And Efficacy in Animal Models

Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Efficacy, Safety, and Stability in Animal Models Three posters presented at NACFC 2016 DURHAM, N.C. – November 2, 2016. Three posters presented by Spyryx Biosciences at the North American Cystic Fibrosis Conference provided data that demonstrates the safety, stability and efficacy of SPX-101 in animal models […]

Continue Reading

Spyryx Biosciences to Present Safety, Stability & Effectiveness Data for SPX-101 at the North American CysticFibrosis Conference October 27-29, 2016 Orlando, FL

DURHAM, N.C., Oct. 25, 2016 /PRNewswire/ — Spyryx Biosciences, a clinical-stage biopharmaceuticalcompany developing first-in-class innovative therapeutics to address severe lung diseases, will present three posters (Abstract numbers 222, 257, 289) on the pharmacology, toxicology, manufacturing scale-up and stability of SPX-101, a SPLUNC1-derived peptide that has the potential to provide disease-modifying therapy to all cystic fibrosis […]

Continue Reading